We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

105 hedge funds and large institutions have $132M invested in VYNE Therapeutics in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.04% less ownership

Funds ownership: 0.7% → 0.66% (-0.04%)

1% less funds holding

Funds holding: 106 → 105 (-1)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

17% less capital invested

Capital invested by funds: $160M → $132M (-$28M)

Holders
105
Holders Change
-1
Holders Change %
-0.94%
% of All Funds
2.12%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
33
Reduced
25
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.64M
2
State Street
State Street
Massachusetts
+$749K
3
6CM
683 Capital Management
New York
+$679K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$594K
5
Northern Trust
Northern Trust
Illinois
+$442K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$2.95M
2
Millennium Management
Millennium Management
New York
-$2.16M
3
CCM
CAAS Capital Management
New York
-$2.05M
4
SI
Sofinnova Investments
California
-$1.26M
5
BBVA
Banco Bilbao Vizcaya Argentaria
Spain
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
101
Millennium Management
New York
$70 -$2.16M -18,491 -97%
CCM
102
CAAS Capital Management
New York
– -$2.05M -16,465 Closed
SI
103
Sofinnova Investments
California
– -$1.26M -10,077 Closed
BBVA
104
Banco Bilbao Vizcaya Argentaria
Spain
– -$1.12M -8,995 Closed
O
105
OrbiMed
New York
– -$1.03M -8,248 Closed
Citadel Advisors
106
Citadel Advisors
Florida
– -$875K -7,020 Closed
Renaissance Technologies
107
Renaissance Technologies
New York
– -$535K -4,295 Closed
Barclays
108
Barclays
United Kingdom
– -$219K -1,748 Closed
MA
109
MYDA Advisors
New York
– -$161K -1,296 Closed
AC
110
Athanor Capital
New York
– -$104K -833 Closed
SG Americas Securities
111
SG Americas Securities
New York
– -$100K -803 Closed
WS
112
Wedbush Securities
California
– -$92K -735 Closed
BFM
113
Boothbay Fund Management
New York
– -$78K -625 Closed
NFG
114
Nations Financial Group
Iowa
– -$66K -528 Closed
GC
115
Grace Capital
Massachusetts
– -$62K -500 Closed
Baird Financial Group
116
Baird Financial Group
Wisconsin
– -$27K -215 Closed
PPCM
117
Pillar Pacific Capital Management
California
– -$23K -188 Closed
PHK
118
Point72 Hong Kong
Hong Kong
– -$14K -113 Closed
AA
119
AlphaMark Advisors
Kentucky
– -$10K -77 Closed
BNP Paribas Financial Markets
120
BNP Paribas Financial Markets
France
– -$9.41K -76 Closed
CAN
121
Cetera Advisor Networks
California
– -$3K -23 Closed
IRC
122
Investors Research Corp
Georgia
– +$350 +3 New
1 2 3 4
5

VYNE Hedge Fund Activity: Q3 2020 in Review

105 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2020, worth a combined $132M — down 17% from $160M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of VYNE and 19 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $2.64M. The largest seller was Vivo Capital, cutting an estimated $2.95M.

  • 105 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2020, down from 106 in Q2 2020.
  • Funds reported $132M of VYNE Therapeutics stock for Q3 2020, down 17% quarter-over-quarter.
  • 19 funds opened new VYNE Therapeutics positions in Q3 2020 and 20 closed out, a net change of -1 holder.
  • The largest VYNE Therapeutics buyer in Q3 2020 was BlackRock, an estimated $2.64M added.
  • The largest VYNE Therapeutics seller in Q3 2020 was Vivo Capital, an estimated $2.95M sold.

Based on aggregated 13F filings for Q3 2020.